title: Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification?
abstract: BACKGROUND
  Response to preoperative radiochemotherapy (RCT) in patients with locally advanced rectal cancer is very heterogeneous. Pathologic complete response (pCR) is accompanied by a favorable outcome. However, most patients show incomplete response. The aim of this investigation was to find indications for risk stratification in the group of intermediate responders to RCT.
  
  
  METHODS
  From a prospective database of 496 patients with rectal adenocarcinoma, 107 patients with stage II/III cancers and intermediate response to preoperative 5-FU based RCT (ypT2/3 and TRG 2/3), treated within the German Rectal Cancer Trials were studied. Surgical treatment comprised curative (R0) total mesorectal excision (TME) in all cases. In 95 patients available for statistical analyses, residual transmural infiltration of the mesorectal compartment, nodal involvement and histolologic tumor grading were investigated for their prognostic impact on disease-free (DFS) and overall survival (OS).
  
  
  RESULTS
  Residual tumor transgression into the mesorectal compartment (ypT3) did not influence DFS and OS rates (p = 0.619, p = 0.602, respectively). Nodal involvement after preoperative RCT (ypN1/2) turned out to be a valid prognostic factor with decreased DFS and OS (p = 0.0463, p = 0.0236, respectively). Persistent tumor infiltration of the mesorectum (ypT3) and histologic tumor grading of residual tumor cell clusters were strongly correlated with lymph node metastases after neoadjuvant treatment (p < 0.001).
  
  
  CONCLUSIONS
  Advanced transmural tumor invasion after RCT does not affect prognosis when curative (R0) resection is achievable. Residual nodal status is the most important predictor of individual outcome in intermediate responders to preoperative RCT. Furthermore, ypT stage and tumor grading turn out to be additional auxiliary factors. Future clinical trials for risk-adapted adjuvant therapy should be based on a synopsis of clinicopathologic parameters.
authors.affiliation: Department of General and Visceral Surgery, University Medical Center Göttingen, Georg-August-University, Göttingen, Germany. tsprenger@chirurgie-goettingen.de
authors.forename: Thilo
authors.initials: T
authors.lastname: Sprenger
authors.forename: Hilka
authors.initials: H
authors.lastname: Rothe
authors.forename: Klaus
authors.initials: K
authors.lastname: Jung
authors.forename: Hans
authors.initials: H
authors.lastname: Christiansen
authors.forename: Lena C
authors.initials: LC
authors.lastname: Conradi
authors.forename: B Michael
authors.initials: BM
authors.lastname: Ghadimi
authors.forename: Heinz
authors.initials: H
authors.lastname: Becker
authors.forename: Torsten
authors.initials: T
authors.lastname: Liersch
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy / Q000628:therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D011300:Preoperative Care; D011446:Prospective Studies; D012004:Rectal Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy / Q000628:therapy*; D018570:Risk Assessment; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D005472:Fluorouracil
references.citation: Ann Surg. 2006 Apr;243(4):492-8
references.pmid: 16552200
references.citation: Surg Today. 2005;35(6):442-5
references.pmid: 15912290
references.citation: Dis Colon Rectum. 2002 Jul;45(7):895-903
references.pmid: 12130878
references.citation: Cancer. 2001 Dec 1;92(11):2754-9
references.pmid: 11753948
references.citation: Cancer. 2008 Jul 1;113(1):57-64
references.pmid: 18442099
references.citation: Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):935-41
references.pmid: 9869213
references.citation: Z Gastroenterol. 2008 Aug;46(8):799-840
references.pmid: 18759205
references.citation: Lancet. 1993 Feb 20;341(8843):457-60
references.pmid: 8094488
references.citation: Dis Colon Rectum. 2006 Sep;49(9):1284-92
references.pmid: 16758130
references.citation: N Engl J Med. 1991 Mar 14;324(11):709-15
references.pmid: 1997835
references.citation: ANZ J Surg. 2002 Jul;72(7):483-7
references.pmid: 12123507
references.citation: Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):426-31
references.pmid: 15667963
references.citation: N Engl J Med. 1997 Apr 3;336(14):980-7
references.pmid: 9091798
references.citation: Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1158-65
references.pmid: 19800178
references.citation: Dis Colon Rectum. 2008 Mar;51(3):277-83
references.pmid: 18183463
references.citation: Cancer. 2005 Feb 1;103(3):647-9
references.pmid: 15612025
references.citation: N Engl J Med. 2004 Oct 21;351(17):1731-40
references.pmid: 15496622
references.citation: Semin Surg Oncol. 2003;21(1):19-22
references.pmid: 12923912
references.citation: Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6617-23
references.pmid: 18006762
references.citation: J Clin Oncol. 2002 Apr 1;20(7):1729-34
references.pmid: 11919228
references.citation: J Clin Oncol. 2001 Jan 1;19(1):157-63
references.pmid: 11134208
references.citation: J Surg Oncol. 2009 Dec 1;100(7):525-8
references.pmid: 19697351
references.citation: J Clin Oncol. 2007 Jan 1;25(1):110-7
references.pmid: 17194912
references.citation: N Engl J Med. 1997 Jul 31;337(5):346-7; author reply 347-8
references.pmid: 9235500
references.citation: Arch Surg. 2002 Feb;137(2):206-10
references.pmid: 11822961
references.citation: J Clin Oncol. 2007 Jun 20;25(18):2573-9
references.pmid: 17577036
references.citation: J Surg Oncol. 2009 Oct 1;100(5):387-91
references.pmid: 19582821
references.citation: Dis Colon Rectum. 1999 Feb;42(2):167-73
references.pmid: 10211491
references.citation: J Clin Oncol. 2005 Dec 1;23(34):8688-96
references.pmid: 16246976
references.citation: Br J Surg. 1982 Oct;69(10):613-6
references.pmid: 6751457
references.citation: J Clin Oncol. 2007 Oct 1;25(28):4379-86
references.pmid: 17906203
references.citation: J Clin Oncol. 2006 Oct 1;24(28):4620-5
references.pmid: 17008704
references.citation: N Engl J Med. 2001 Aug 30;345(9):638-46
references.pmid: 11547717
references.citation: Int J Colorectal Dis. 1997;12(1):19-23
references.pmid: 9112145
references.citation: Cancer. 2009 Dec 1;115(23):5432-40
references.pmid: 19673001
references.citation: Ann Surg. 2009 Jun;249(6):965-72
references.pmid: 19474683